Protocol 331-13-002: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
Latest Information Update: 06 Nov 2016
Price :
$35 *
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Anxiety; Major depressive disorder
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 20 Sep 2016 Results from this and other two open label studies ( profiles 239811 and 240179), presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
- 12 May 2015 The results of this trial will be presented at the American Psychiatric Association annual meeting, according to an Otsuka and Lundbeck media release.
- 04 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.